All In Biotech

Drug Trial Radar · NCT05540860

A Study of EDG-5506 in Children With Duchenne Muscular Dystrophy (LYNX)

A 2-part Phase 2 Study of Safety, Pharmacokinetics and Biomarkers in Children With Duchenne Muscular Dystrophy Including a Randomized, Double-Blind, Placebo-Controlled Part A, Followed by an Open-Label Part B

Last checked: Nov 19, 2026Latest source record: Nov 12, 2025 (this record)Source: ClinicalTrials.govMethods & limitations

Active, not recruiting

Status

Active, not recruiting

Enrollment

76

Actual

Start

Oct 24, 2022

Primary completion

Jan 2027

Study completion Jan 2027

Sponsor

Lead sponsor
Edgewise Therapeutics, Inc.Industry
Sponsor type
Industry
First posted
Sep 15, 2022

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 2
Allocation
Randomized
Model
Sequential
Masking
Quadruple (participant, care provider, investigator, outcomes assessor)
Primary purpose
Treatment
FDA-regulated drug
Yes
Who can join
Male only, from 4 years, up to 9 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

The LYNX study is a 2-part, multicenter, Phase 2 study of safety, pharmacokinetics and biomarkers in children with Duchenne muscular dystrophy including a randomized, double-blind, placebo-controlled part A, followed by an open-label part B.

Conditions

  • Duchenne Muscular Dystrophy

Interventions

  • Sevasemten Dose 1Drug

    Sevasemten is administered orally once per day

  • Sevasemten Dose 2Drug

    Sevasemten is administered orally once per day

  • Sevasemten Dose 3Drug

    Sevasemten is administered orally once per day

  • Sevasemten Dose 4Drug

    Sevasemten is administered orally once per day

  • Sevasemten Dose 5Drug

    Sevasemten is administered orally once per day

  • PlaceboDrug

    Placebo is administered orally once per day

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Number of adverse events during treatment with sevasemten or placeboTime frame: 48 months
  2. Severity of adverse events during treatment with sevasemten or placeboTime frame: 48 months

Locations

14 sites in 1 country. Site status is shown where the registry gives one.

  • Arkansas Children's Hospital

    Little Rock, Arkansas

  • UCLA Medical Center

    Los Angeles, California

  • UC Davis Medical Center

    Sacramento, California

  • Children's Hospital Colorado

    Aurora, Colorado

  • University of Florida

    Gainesville, Florida

  • Rare Disease Research

    Atlanta, Georgia

  • University of Iowa

    Iowa City, Iowa

  • University of Kansas Medical Center

    Kansas City, Kansas

  • Kennedy Krieger Institute

    Baltimore, Maryland

  • University of Massachusetts Memorial Medical Center

    Worcester, Massachusetts

  • Washington University School of Medicine

    St Louis, Missouri

  • Cincinnati Children's Hospital

    Cincinnati, Ohio

  • Nationwide Children's Hospital

    Columbus, Ohio

  • Cook Children's Medical Center

    Fort Worth, Texas

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.